Molecular genetics of ovarian cancer

被引:0
|
作者
Andrew N. Shelling
William Foulkes
机构
[1] National Women’s Hospital,Centre in Reproductive Medicine, Department of Obstetrics and Gynaecology
来源
Molecular Biotechnology | 2001年 / 19卷
关键词
Ovarian cancer; molecular genetics; gene identification; mutation screening;
D O I
暂无
中图分类号
学科分类号
摘要
This is a review of the approaches that can be used to analyze genetic changes in ovarian cancer. Traditional gene localization methods are discussed, followed by a section on gene identification techniques. Once a putative disease-associated gene has been cloned, mutations have to be identified and analyzed. There are numerous mutation detection methods, and the most common ones are outlined. In the penultimate section, the role of immunohistochemistry as a surrogate method for mutation analysis is considered. Finally, the possible use of functional assays is discussed. At present, it would appear that DNA chip technology for the detection of mutations, and microarray analysis of gene expression, are two important techniques likely to have a significant impact on the genetic analysis of ovarian cancer.
引用
收藏
页码:13 / 28
页数:15
相关论文
共 50 条
  • [41] Molecular predictors of response and outcome in ovarian cancer
    Canevari, Silvana
    Gariboldi, Manuela
    Reid, James F.
    Bongarzone, Italia
    Pierotti, Marco A.
    CRITICAL REVIEWS IN ONCOLOGY HEMATOLOGY, 2006, 60 (01) : 19 - 37
  • [42] Molecular Biomarkers for the Early Detection of Ovarian Cancer
    Zhang, Ruiqian
    Siu, Michelle K. Y.
    Ngan, Hextan Y. S.
    Chan, Karen K. L.
    INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES, 2022, 23 (19)
  • [43] Molecular mechanisms of cisplatin resistance in ovarian cancer
    Jiang, Chenying
    Shen, Chenjun
    Ni, Maowei
    Huang, Lili
    Hu, Hongtao
    Dai, Qinhui
    Zhao, Huajun
    Zhu, Zhihui
    GENES & DISEASES, 2024, 11 (06)
  • [44] Molecular determinants of chemotherapy resistance in ovarian cancer
    Cooley, Megan
    Fang, Pingping
    Fang, Fang
    Nephew, Kenneth P.
    Chien, Jeremy
    PHARMACOGENOMICS, 2015, 16 (16) : 1763 - 1767
  • [45] Molecular profiling of platinum resistant ovarian cancer
    Helleman, J
    Jansen, MPHM
    Span, PN
    van Staveren, IL
    Massuger, LFAG
    Gelder, MEMV
    Sweep, FCGJ
    Ewing, PC
    van der Burg, MEL
    Stoter, G
    Nooter, K
    Berns, EMJJ
    INTERNATIONAL JOURNAL OF CANCER, 2006, 118 (08) : 1963 - 1971
  • [46] Molecular mechanisms of drug resistance in ovarian cancer
    Norouzi-Barough, Leyla
    Sarookhani, Mohammad Reza
    Sharifi, Mohammadreza
    Moghbelinejad, Sahar
    Jangjoo, Saranaz
    Salehi, Rasoul
    JOURNAL OF CELLULAR PHYSIOLOGY, 2018, 233 (06) : 4546 - 4562
  • [47] Editorial: Molecular influences in therapies in ovarian cancer
    Restaino, Stefano
    Wei, Jian-Jun
    Vizzielli, Giuseppe
    Martinelli, Fabio
    FRONTIERS IN ONCOLOGY, 2022, 12
  • [48] Epidemiological and molecular aspects of ovarian cancer risk
    Runnebaum, IB
    Stickeler, E
    JOURNAL OF CANCER RESEARCH AND CLINICAL ONCOLOGY, 2001, 127 (02) : 73 - 79
  • [49] Mainstreaming cancer genetics: A model integrating germline BRCA testing into routine ovarian cancer clinics
    Kentwell, Maira
    Dow, Eryn
    Antill, Yoland
    Wrede, C. David
    McNally, Orla
    Higgs, Emily
    Hamilton, Anne
    Ananda, Sumitra
    Lindeman, Geoffrey J.
    Scott, Clare L.
    GYNECOLOGIC ONCOLOGY, 2017, 145 (01) : 130 - 136
  • [50] Molecular-targeted therapies for ovarian cancer
    Junzo Kigawa
    International Journal of Clinical Oncology, 2012, 17 : 423 - 423